Amalgamated Financial’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Amalgamated Financial’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$5K	Buy	+3,266	New	+$5.83K	﹤0.01%	2967

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's KLDO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2022: 3,266 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #2967 among its holdings.

63 funds tracked by Wall St. Rank hold KLDO as of Q1 2022.

Amalgamated Financial held 3,266 shares of Kaleido Biosciences, Inc. Common Stock worth $5K as of Q1 2022.
Kaleido Biosciences, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Kaleido Biosciences, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2967 holding.
63 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.